1,236
Views
14
CrossRef citations to date
0
Altmetric
Point-of-View

Molecular dissection of CHARGE syndrome highlights the vulnerability of neural crest cells to problems with alternative splicing and other transcription-related processes

& ORCID Icon
Pages 21-28 | Received 30 Jul 2018, Accepted 29 Aug 2018, Published online: 20 Sep 2018

Figures & data

Figure 1. Potential mode of action of Fam172a in Ago2-mediated alternative splicing. Although the relationship between all players shown remains to be characterized in detail, current data suggest that the presence of Fam172a at the chromatin-spliceosome interface helps stabilizing protein-protein interactions between the small-RNA binding protein Ago2, chromatin remodelers such as Chd7 and histone modifiers such as Ehmt2. Model adapted from Refs [Citation22,Citation24].

Figure 1. Potential mode of action of Fam172a in Ago2-mediated alternative splicing. Although the relationship between all players shown remains to be characterized in detail, current data suggest that the presence of Fam172a at the chromatin-spliceosome interface helps stabilizing protein-protein interactions between the small-RNA binding protein Ago2, chromatin remodelers such as Chd7 and histone modifiers such as Ehmt2. Model adapted from Refs [Citation22,Citation24].

Table 1. Clinical and molecular overlap between CHARGE syndrome and other rare conditions.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.